Generic medicines: Solutions for a sustainable drug market?

Applied Health Economics and Health Policy

Volumn 11, Issue 5, 2013, Pages 437-443

  Dylst, Pieter ^a   Vulto, Arnold ^b   Godman, Brian ^c,d,e   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORPHAN DRUG; PROTON PUMP INHIBITOR;

COST CONTROL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; PERCEPTION; REIMBURSEMENT; REVIEW;

ATTITUDE TO HEALTH; COST SAVINGS; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; FORECASTING; HUMANS; MARKETING;

EID: 84885853720     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0043-z     Document Type: Review

References (60)

1. Sollano JA, Kirsch JM, Bala MV, Chambers MG, Harpole LH. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Clin Pharmacol Ther. 2008;84(2):263-6.
2. Arrowsmith J. A decade of change. Nat Rev Drug Discovery. 2012;11:17-8.
3. Dylst P, Simoens S. Does the market share of generic medicines influence the price level? A European analysis. Pharmacoeconomics. 2011;29(10):875-82.
4. Henry D, Lexchin J. The pharmaceutical industry as a medicines provider. Lancet. 2002;360:1590-5.
5. Sermet C, Andrieu V, Godman B, van Ganse E, Haycox A, Reynier J. Ongoing pharmaceutical reforms in France: implications for key stakeholders. Applied Health Economics and Health Policy. 2010;8(1):7-24.
6. Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Weininger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res. 2008;8(4):357-71.
7. Godman B, Paterson K, Malmström R, Selke G, Fagot J, Mrak J. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439-41.
8. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65-83.
9. Godman B, Gustafsson LL. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy. 2013;11(79):82.
10. European Commission. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the community code relating to medicinal products for human use. Off J Eur Union L 136/34-57. 2004.
11. Baumgärtel C, Godman B, Malmström R, Andersen M, Abuelkhair M, Abdu S, et al. What lessons can be learned from the launch of generic clopidogrel. GaBi J. 2012;1(2):58-68.
12. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European contries - an overview. GaBi J. 2012;1(2):93-100.
13. Simoens S. International comparison of generic medicine prices. Curr Med Res Opin. 2007;23(11):2647-54.
14. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J Generic Med. 2006;3(4):257-68.
15. Godman B, Abuelkhair M, Vitry A, Abdu S, Bennie M, Bishop I, et al. Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. GaBi J. 2012;1(2):69-83.
16. van Woerkom M, Piepenbrink H, Godman B, de Metz J, Campbell S, Bennie M, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res. 2012;1(6):527-38.
17. Godman B, Bennie M, Baumgärtel C, Sovic-Brkicic L, Burkhardt T, Fürst J, et al. Essential to increase the use of generics in Europe to maintain comprehensive health care. Farmeconomia Health Econ Ther Pathw. 2012;13(3):5-20.
18. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):125-30.
19. Gumbs P, Verschuren M, Souverein P, Mantel-Teeuwisse A, de Wit A, de Boer A, et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol. 2007;64(5):680-5.
20. Anonymous. Dutch body counts off-patent savings. News@Genericsbulletin 2013.
21. Anonymous. German savings exceed EUR2 billion. News@Genericsbulletin 2013.
22. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele' V. Recent national and regional drug reforms in Sweden - implication for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26:537-50.
23. Tilson L, Bennett K, Barry M. The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland. Eur J Health Econ. 2005;50:267-73.
24. Ubeda A, Cardo E, Sellés N, Broseta R, Trillo JL, Fernández-Llimós F. Antidepressant utilization in primary care in a Spanish region. Impact of generic and reference-based pricing policy (2000-2004). Soc Psychiatry Psychiatr Epidemiol. 2007;42:181-8.
25. Simoens S, De Coster S. Potential savings from increased substitution of generic for originator medicines in Europe. J Generic Med. 2006;4(1):43-5.
26. Generic Pharmaceutical Association. Generic drug savings in the US: 1 trillion over 10 years. Washington, DC, United States: Generic Pharmaceutical Association; 2012.
27. Harisson C. Dangling from the patent cliff. Nat Rev Drug Discovery. 2013;12:14-5.
28. Shrank W, Hoang T, Ettner S, Glassman P, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166:332-7.
29. Taylor L. Australian government blocks subsidies for new drugs. Pharmatimes 2011.
30. Garuolienè K, Alonderis T, Marcinkevicius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth. 2011;17:1-4.
31. Espin J, Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Brussel, Belgium, DG Enterprise and Industry of the European Commission. 2007. pp. 1-219.
32. European Commission. Pharmaceutical Sector Inquiry: Final report. 1-533. Brussels, Belgium: European Commission; 2009.
33. Godman B. Health authority perspective on biosimilars. GaBi J. 2013;2(1):10-1.
34. Declerck P, Simoens S. A European perspective on the market accessibility of biosimilars. Biosimilars. 2012;2:33-40.
35. EvaluatePharma. Surveying tomorrow's BioPharma landscape: The NASDAQ Biotech Index up close. London, United Kingdom, EvaluatePharma; 2012
36. Dylst P, Vulto A, Simoens S. Overcoming challenges in market access of generic medicines in the European Union. J Generic Med. 2012;9(1):21-8.
37. European Parliament. European Parliament legislative resolution of 6 February 2013 on the proposal for a directive of the European Parliament and of the Council relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of public health insurance systems (COM(2012)0084-C7-0056/2012-2012/0035(COD)). http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language= EN&reference=P7-TA-2013-39. 2013. Brussels, Belgium, European Parliament.
38. Anonymous. EU endorses latest unitary patent plan. Generics Bull 2012;9.
39. Fox B. 'Historic day' as EU patent deal ends 40-year wait. http://euobserver.com 2012.
40. European Generic Medicines Association. How to increase patient access to generic medicines in European healthcare systems. Brussels, Belgium: European Generic Medicines Association; 2009.
41. Boonen L, van der Geest S, Schut F, Varkevisser M. Pharmaceutical policy in The Netherlands: from price regulation towards managed competition. Adv Health Econ Health Serv Res. 2010;22:53-76.
42. Apotex. Press release; 2009.
43. Anonymous. Canada chooses cuts over tendering model. Generics Bull 2013;1.
44. Anonymous. Spanish government introduces harsh generic price cuts. GaBi online: generics and biosimilars initiative. 2010.
45. Leopold C, Vogler S, Mantel-Teeuwisse A, de Joncheere K, Leufkens H, Laing R. Differences in external price referencing in Europe - a descriptive overview. Health Policy. 2012;104:50-60.
46. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):59-72.
47. Windmeijer F, de Laat E, Douven R, Mot E. Pharmaceutical promotion and GP prescription behavior. Health Econ. 2006;15:5-18.
48. Lundin D. Moral hazard in physician prescription behavior. J Health Econ. 2000;19:639-62.
49. Kesselheim A, Misono A, Lee J, Stedman M, Brookhart A, Choudry N, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. J Am Med Assoc. 2008;300(21):2514-26.
50. Kesselheim A, Stedman M, Bubrick E, Gagne J, Misono A, Lee J, et al. Seizure outcomes following use of generic vs. brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70(5):605-21.
51. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol. 2011;1:1-16.
52. Voncina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):469-79.
53. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(1):73-85.
54. Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, Hasselström J, et al. The 'wise list' - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108:224-33.
55. Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, et al. Use of generics - a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3:2470-94.
56. Olsson E, Sporrong SK. Pharmacists' experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract. 2012;20:377-83.
57. Dylst P, Vulto A, Simoens S. How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing? Pharm Pract. 2012;10(1):3-8.
58. Reinke T. Biosimilars might not measure up to health plan expectations. Managed Care. 2012;21(10):12-3.
59. Höer A, de Millas C, Häussler B, Haustein R. Saving money in the European healthcare systems with biosimilars. GaBi J. 2012;3-4:120-6.
60. European Medicines Agency. European Medicines Agency recommends granting a marketing authorization to Imatinib TEVA. 2013.